AB
KNSA icon

Amalgamated Bank’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Amalgamated Bank’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,328
Closed -$29K – 3075
2025
Q1 		$29K Buy
1,328
+212
+19% +$4.36K ﹤0.01% 1947
2024
Q4 		$22K Hold
1,116
– – ﹤0.01% 2084
2024
Q3 		$28K Hold
1,116
– – ﹤0.01% 2012
2024
Q2 		$21K Buy
1,116
+101
+10% +$1.89K ﹤0.01% 2099
2024
Q1 		$20K Sell
1,015
-1,679
-62% -$32.8K ﹤0.01% 2127
2023
Q4 		$47K Sell
2,694
-302
-10% -$4.96K ﹤0.01% 2281
2023
Q3 		$52K Hold
2,996
– – ﹤0.01% 2238
2023
Q2 		$42K Sell
2,996
-1,208
-29% -$16.2K ﹤0.01% 2396
2023
Q1 		$45K Sell
4,204
-656
-13% -$8.64K ﹤0.01% 2346
2022
Q4 		$73K Hold
4,860
– – ﹤0.01% 2268
2022
Q3 		$62K Buy
4,860
+72
+2% +$820 ﹤0.01% 2364
2022
Q2 		$46K Buy
4,788
+695
+17% +$6.49K ﹤0.01% 2528
2022
Q1 		$41K Buy
+4,093
New +$43.4K ﹤0.01% 2566

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Amalgamated Bank's KNSA Position: Q2 2025 in Review

Amalgamated Bank sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2025, closing a stake of 1,328 shares — an estimated $29K sold.

Amalgamated Bank first reported a position in KNSA in Q1 2022 and held it in 13 quarters. The position peaked at $73K in Q4 2022. 189 funds tracked by Wall St. Rank hold KNSA as of Q2 2025.

  • Amalgamated Bank reported no remaining Kiniksa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 1,328 Kiniksa Pharmaceuticals shares in Q2 2025, an estimated $29K.
  • Amalgamated Bank first reported a position in Kiniksa Pharmaceuticals in Q1 2022 and held it in 13 quarters.
  • Amalgamated Bank's Kiniksa Pharmaceuticals position peaked at $73K in Q4 2022.
  • 189 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.